H
Hiroaki Shimokawa
Researcher at Tohoku University
Publications - 976
Citations - 56856
Hiroaki Shimokawa is an academic researcher from Tohoku University. The author has contributed to research in topics: Heart failure & Endothelium. The author has an hindex of 111, co-authored 949 publications receiving 48822 citations. Previous affiliations of Hiroaki Shimokawa include University of Nebraska Medical Center & Nagoya University.
Papers
More filters
Journal ArticleDOI
1343Evidence for impaired vasodilator capacity of coronary microvessels in patients with vasospatic angina - Myocardial CT perfusion imaging study
Jun Sugisawa,Yotaro Matsumoto,Akira Suda,Hideki Ota,Satoshi Tsuchiya,Kazuma Ohyama,Kenjiro Sato,Tomohiko Shindo,Shohei Ikeda,Kiyotaka Hao,Yoku Kikuchi,Jun Takahashi,Hiroaki Shimokawa +12 more
Journal ArticleDOI
Phosphorylated Rho-kinase (ROCK) as a novel therapeutic target in treatment of breast cancer
Satoko Shiotani,Noriaki Sadanaga,Keizo Sugimachi,S. Okada,Eriko Tokunaga,Eiji Oki,Hiroaki Shimokawa,Y. Maehara +7 more
TL;DR: The enhanced immunoreactivity of p-ROCK (>20% positive area in total high-power field) was frequently observed in patients with breast cancer and was analyzed in terms of the clinicopathological factors and survival of the patients in the 3-years follow-up period after the operation.
Journal ArticleDOI
P3575Clinical importance of fractional flow reserve in patients with organic coronary stenosis and vasospastic angina
Kiyotaka Hao,Jun Takahashi,Akira Suda,Kenjiro Sato,Jun Sugisawa,Satoshi Tsuchiya,Tomohiko Shindo,Shohei Ikeda,Yoku Kikuchi,Takashi Shiroto,Yotaro Matsumoto,Yasuhiko Sakata,Hiroaki Shimokawa +12 more
TL;DR: Examining the clinical importance and prognostic impact of fractional flow reserve (FFR) in patients with VSA and organic coronary stenosis provides the first evidence that evaluation of coronary functional abnormalities with FFR is useful for making therapeutic strategies in VSA patients with organic stenosis.
Proceedings ArticleDOI
Role of endogenous hydrogen peroxide during angiotensin type 1 receptor blockers administration in pacing-induced metabolic coronary vasodilatation in dogs in vivo
TL;DR: In this paper, the role of H2O2/EDHF during angiotensin type 1 receptor blockers (ARB) administration in metabolic coronary dilatation in vivo remains to be examined.
Journal ArticleDOI
[ACTION study: efficacy of nifedipine in preventing cardiovascular disease in patients with coronary artery disease].
TL;DR: Data indicate that a direct action on blood vessels, rather than coronary vasodilating or antihypertensive effects, might be responsible for improved prognosis with nifedipine.